|
Respiratory syncytial virus Articles
Respiratory syncytial virus News : Officials warn of virus Wed, 10 Mar 2010 12:29:56 GMT Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV). CMX001 is a broad-spectrum antiviral agent with demonstrated activity against double-stranded DNA (dsDNA) viruses...Respiratory syncytial virus News : Discovery Labs Reports Fourth Quarter 2009 Financial Results and Provides Business Update Wed, 10 Mar 2010 12:45:00 GMT WARRINGTON, Pa. -- Discovery Laboratories, Inc. today announces financial results for the fourth quarter ended December 31, 2009 and provides a business update.Holiens share Keira’s story Wed, 10 Mar 2010 06:33:10 GMT Looking at three-year-old Keira Holien bounce around the room, it’s hard to tell she spent the first two months of her life fighting for every breath. Keira was born with Down Syndrome and three holes in her heart.Despite Potential of RNAi, Companies in the Space Keep Pipelines Focused Tue, 09 Mar 2010 22:20:38 GMT With its ability to down-regulate almost any gene of interest, RNAi has been touted as a technology with almost limitless therapeutic potential, capable of hitting targets that have eluded traditional modalities such as small molecules.Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus Tue, 09 Mar 2010 15:14:03 GMT RESEARCH TRIANGLE PARK, N.C., March 9 /PRNewswire/ -- Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus (CMV). CMX001 is a broad-spectrum antiviral agent with demonstrated activity ...Alnylam to Webcast Presentation at the 22nd Annual ROTH OC Growth Stock Conference Tue, 09 Mar 2010 21:00:00 GMT CAMBRIDGE, Mass.----Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that management will present a company overview at the 22nd Annual ROTH OC Growth Stock Conference on Tuesday, March 16, 2010, at 3:00 p.m.Chimerix Initiates Phase 2 Study of CMX001 in Stem Cell Transplant Recipients Seropositive for Cytomegalovirus Tue, 09 Mar 2010 13:30:00 GMT Chimerix, Inc., a biotechnology company developing orally-available antiviral therapeutics, today announced the initiation of a multi-center Phase 2 clinical trial designed to evaluate CMX001 in stem cell transplant recipients who are seropositive for cytomegalovirus .GenVec to Present at the ROTH 22nd Annual Orange County Growth Stock Conference Tue, 09 Mar 2010 12:54:00 GMT GenVec, Inc. today announced that Douglas J. Swirsky, Senior Vice President and Chief Financial Officer, will present a company overview highlighting recent developments at the ROTH 22nd Annual Orange County Growth Stock Conference on Tuesday, March 16, 2010 at 10:00 a.m.Jean Barton: Reproductive herd health Mon, 08 Mar 2010 13:59:29 GMT We had 6.45 inches of rain in February, and .7 came on Friday afternoon. The spring has been so cold that the wild flowers are just starting to bloom. The yellow goldfields, a little daisy are starting to color, and you can spot the white shooting stars in sheltered areas.Reportlinker Adds Global Anti-Infectives Industry Mon, 08 Mar 2010 15:45:00 GMT Reportlinker.com announces that a new market research report is available in its catalogue:Study finds BRD and IBR rife in beef cattle Fri, 05 Mar 2010 13:58:30 GMT Bovine respiratory disease (BRD) can reduce growth rates by up to 200g a day and cost £82 a calf, said Fergal Morris, Intervet Schering-Plough, speaking at the recent Beef Expo Northern Ireland , Dungannon.Primary Children's expands to Riverton Sat, 06 Mar 2010 00:14:16 GMT Riverton » Children suffering from a lung infection called RSV and overtaking Primary Children's Medical Center in Salt Lake City will have a new option for getting their oxygen treatments next winter: For the first time, the state's only pediatric hospital will open an inpatient satelliteGenVec to Host Fourth Quarter and Year-End 2009 Earnings Call and Webcast Fri, 05 Mar 2010 15:14:42 GMT GAITHERSBURG, Md., March 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the fourth quarter and year ended December 31, 2009 on Thursday, March 11, 2010 after market close. GenVec will hold a conference call at 10:00 a.m.GenVec to Host Fourth Quarter and Year-End 2009 Earnings Call and Webcast Fri, 05 Mar 2010 16:39:53 GMT GAITHERSBURG, Md., March 5 /PRNewswire-FirstCall/ -- GenVec, Inc. (Nasdaq: GNVC) announced that it will release financial results for the fourth quarter and year ended December 31, 2009 on Thursday, M...Alnylam Execs Foresee Partnerships in 2010, Provide Few Details as Pipeline Advances Wed, 03 Mar 2010 21:35:30 GMT Alnylam Pharmaceuticals expects to forge new collaborations over 2010, but company officials last week declined to provide specific guidance on its partnering objectives after falling short of previous expectations.Death by Study Wed, 03 Mar 2010 20:39:55 GMT Scientists keep fighting to explain high instances of childhood leukemia in Sierra Vista—even as the government has given up by Tim Vanderpool It's late in the day, and I'm on the phone with Pat Durkit. We have never met. But immediately I know this: She's one of those people whose steadfast pleasantness is actually brute resistance, a refusal to accept just how hideous the world can become ...Press Release Wed, 03 Mar 2010 16:51:40 GMT Alnylam Pharmaceuticals Inc. Posted on:03 Mar 10 Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced that management will present a company overview at Cowen and Company’s 30th Annual Health Care Conference on Tuesday, March 9, 2010, at 4:30 p.m. ET at the Boston Marriott Copley Place.AstraZeneca cutting 550 RD jobs Wed, 03 Mar 2010 12:31:49 GMT AstraZeneca announced it will cut back research in Delaware. An estimated 550 jobs will be eliminated over the next two years in Delaware. AstraZeneca is closing research sites in Europe and will add some jobs in Boston.Alnylam to Webcast Presentation at Cowen and Company's 30th Annual Health Care Conference Wed, 03 Mar 2010 14:00:00 GMT CAMBRIDGE, Mass.----Alnylam Pharmaceuticals, Inc. , a leading RNAi therapeutics company, today announced that management will present a company overview at Cowen and Company’s 30th Annual Health Care Conference on Tuesday, March 9, 2010, at 4:30 p.m.New Research Reveals Mechanism By Which TNFerade(TM) Suppresses Metastases Wed, 03 Mar 2010 13:23:00 GMT GenVec, Inc. announced the publication of new preclinical research revealing mechanisms by which TNFerade suppresses cancer metastases through activation of the immune system. |
Infectious and parasitic diseases |
|
|
< Home > |
||